SNDZ Sunridge International Inc (CE)

FOUNTAIN HILLS, Ariz., Oct. 4 /PRNewswire/ -- Sunridge International (OTC Bulletin Board: SNDZ), announced today that successful negotiations have concluded with the signing of exclusive distribution rights to its PNT product line in Bangladesh.  The agreement has been reached between Sunridge and New Amsterdam Marketing (NAM), its current exclusive distributor in India.

"There has been a large increase in interest in our PNT product line and glaucoma treatment, ever since NAM starting its marketing rollout in neighboring India last month," states G. Richard Smith, CEO of Sunridge.  Mr. Smith goes on to say, "that NAM's marketing plan is both impressive and aggressive, and that their sales have already surpassed original estimates."  

"Bangladesh is the sixth largest country in the world by population, and should be a major market for our two-minute non-invasive glaucoma treatment, and a significant revenue stream for our company," states Mr. Smith.

Leo D. Bores, M.D., a medical consultant for Sunridge, will be traveling throughout India for the next two weeks working with NAM's personnel, training doctors, treating patients and providing informational seminars to the public.  NAM's personnel have stated, that Dr. Bores's schedule will likely be changed to include stops in Bangladesh.

Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International (www.oi-pnt.com).

For full details of PNT and its application, we invite you to visit Sunridge International's website at www.sunridgeint.com.

SOURCE Sunridge International